Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...

A missed medical college admission propelled Kiran Mazumdar-Shaw towards a different path, ultimately leading to the founding of Biocon. Re...

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...

Biocon Biologics is expanding its partnership with Civica. This new agreement will bring affordable Insulin Glargine to patients in the Uni...

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...

Biocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...

The licensing agreement, signed between Biocon Biologics’ subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis, would make Biocon Biologics o...

The biotechnology major and pharmaceutical company Mylan N V announced the launch of their insulin biosimilar Semglee.

The integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...

The drug, manufactured by Biocon at its large scale biopharmaceutical facility in Johor, Malaysia, is the country's first locally manufactu...

Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.

BMS had taken a wider decision to sell its entire diabetes franchise to British drug maker AstraZeneca, while narrowing its own focus on de...

Biocon said it has entered into a co-development and commercialization alliance with PiSA of Mexico for recombinant human insulin aimed at ...

Biocon CMD Kiran Mazumdar-Shaw said: "The data is extremely promising and based on what we know today Tregopil may be positioned as a uniqu...

Galactus by PiSA is the first insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, it adde...

Biocon is altering its product commercialisation strategy by eyeing to partner with many regional players rather than joining hands with a ...